Drug combination for recurrent glioma
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of three drugs—valproic acid, irinotecan, and simvastatin—to see if they can help people whose brain tumor (glioma) has come back despite earlier treatment. The goal is to slow or stop tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with glioblastoma or an IDH-mutated glioma.
- If you have glioblastoma, you must have already received at least one prior treatment, including temozolomide or radiation.
- If you have an IDH-mutated glioma, you must have already had both radiation and chemotherapy (an alkylating agent).
- Your tumor must have shown clear signs of growth on an MRI within the last four weeks.
- You must have at least one tumor area that can be measured on an MRI.
- You cannot have taken irinotecan before, or valproic acid within the last two months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
This trial tests a new combination of two drugs, entacapone and bevacizumab, for people whose glioblastoma (a type of brain tumor) has returned after initial treatment. The goal is to see if this combination can help control the tumor and improve outcomes.
This trial tests a combination of two drugs—azacitidine and nivolumab—given directly into the spinal fluid for people whose high-grade glioma has come back after initial treatment. The goal is to see if this approach can safely target the tumor and slow its growth.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This trial tests a combination of two drugs—sintilimab (an immunotherapy that helps your immune system fight cancer) and low-dose bevacizumab (which blocks blood vessel growth to tumors)—for people whose glioblastoma has returned after standard treatment. The goal is to see if this combo can slow or stop the cancer with fewer side effects.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.